TY - JOUR
T1 - Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis
T2 - a systematic review and meta-analysis of randomised controlled trials
AU - Heerspink, Hiddo J.Lambers
AU - Ninomiya, Toshiharu
AU - Zoungas, Sophia
AU - de Zeeuw, Dick
AU - Grobbee, Diederick E.
AU - Jardine, Meg J.
AU - Gallagher, Martin
AU - Roberts, Matthew A.
AU - Cass, Alan
AU - Neal, Bruce
AU - Perkovic, Vlado
N1 - Funding Information:
HJLH was supported by a Fellowship from the Saal van Zwanenburg Stichting, Dutch Kidney Foundation, and International Society of Hypertension Visiting Postdoctoral Fellowship awarded by the Foundation for High Blood Pressure Research Council of Australia. SZ was supported by a National Health and Medical Research Council of Australia Health Professional Research Fellowship. VP was supported by a National Heart Foundation of Australia AstraZeneca research fellowship. AC was supported by a National Health and Medical Research Council of Australia Senior Research Fellowship. This work was supported in part by a National Health and Medical Research Council of Australia Program grant (ID number 571281).
PY - 2009
Y1 - 2009
N2 - Background: Patients undergoing dialysis have a substantially increased risk of cardiovascular mortality and morbidity. Although several trials have shown the cardiovascular benefits of lowering blood pressure in the general population, there is uncertainty about the efficacy and tolerability of reducing blood pressure in patients on dialysis. We did a systematic review and meta-analysis to assess the effect of blood pressure lowering in patients on dialysis. Methods: We systematically searched Medline, Embase, and the Cochrane Library database for trials reported between 1950 and November, 2008, without language restriction. We extracted a standardised dataset from randomised controlled trials of blood pressure lowering in patients on dialysis that reported cardiovascular outcomes. Meta-analysis was done with a random effects model. Findings: We identified eight relevant trials, which provided data for 1679 patients and 495 cardiovascular events. Weighted mean systolic blood pressure was 4·5 mm Hg lower and diastolic blood pressure 2·3 mm Hg lower in actively treated patients than in controls. Blood pressure lowering treatment was associated with lower risks of cardiovascular events (RR 0·71, 95% CI 0·55-0·92; p=0·009), all-cause mortality (RR 0·80, 0·66-0·96; p=0·014), and cardiovascular mortality (RR 0·71, 0·50-0·99; p=0·044) than control regimens. The effects seem to be consistent across a range of patient groups included in the studies. Interpretation: Treatment with agents that lower blood pressure should routinely be considered for individuals undergoing dialysis to reduce the very high cardiovascular morbidity and mortality rate in this population. Funding: National Health and Medical Research Council of Australia Program.
AB - Background: Patients undergoing dialysis have a substantially increased risk of cardiovascular mortality and morbidity. Although several trials have shown the cardiovascular benefits of lowering blood pressure in the general population, there is uncertainty about the efficacy and tolerability of reducing blood pressure in patients on dialysis. We did a systematic review and meta-analysis to assess the effect of blood pressure lowering in patients on dialysis. Methods: We systematically searched Medline, Embase, and the Cochrane Library database for trials reported between 1950 and November, 2008, without language restriction. We extracted a standardised dataset from randomised controlled trials of blood pressure lowering in patients on dialysis that reported cardiovascular outcomes. Meta-analysis was done with a random effects model. Findings: We identified eight relevant trials, which provided data for 1679 patients and 495 cardiovascular events. Weighted mean systolic blood pressure was 4·5 mm Hg lower and diastolic blood pressure 2·3 mm Hg lower in actively treated patients than in controls. Blood pressure lowering treatment was associated with lower risks of cardiovascular events (RR 0·71, 95% CI 0·55-0·92; p=0·009), all-cause mortality (RR 0·80, 0·66-0·96; p=0·014), and cardiovascular mortality (RR 0·71, 0·50-0·99; p=0·044) than control regimens. The effects seem to be consistent across a range of patient groups included in the studies. Interpretation: Treatment with agents that lower blood pressure should routinely be considered for individuals undergoing dialysis to reduce the very high cardiovascular morbidity and mortality rate in this population. Funding: National Health and Medical Research Council of Australia Program.
UR - http://www.scopus.com/inward/record.url?scp=62349103944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=62349103944&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(09)60212-9
DO - 10.1016/S0140-6736(09)60212-9
M3 - Article
C2 - 19249092
AN - SCOPUS:62349103944
SN - 0140-6736
VL - 373
SP - 1009
EP - 1015
JO - The Lancet
JF - The Lancet
IS - 9668
ER -